Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Jul 17, 2024

SELL
$0.48 - $7.8 $4 - $78
-10 Closed
0 $0
Q3 2021

Jul 17, 2024

SELL
$1.15 - $1.57 $6 - $9
-6 Reduced 37.5%
10 $12,000
Q2 2021

Jul 17, 2024

BUY
$1.4 - $1.9 $8 - $11
6 Added 60.0%
16 $10,000
Q1 2019

Jul 17, 2024

BUY
$3.48 - $5.32 $34 - $53
10 New
10 $36,000

About CALADRIUS BIOSCIENCES, INC.


  • Ticker CLBS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,583,200
  • Market Cap $25.8M
  • Description
  • Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...
More about CLBS
Track This Portfolio

Track Kelly Financial Services LLC Portfolio

Follow Kelly Financial Services LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kelly Financial Services LLC with notifications on news.